Clinical Trial Detail

NCT ID NCT03050814
Title Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

Therapies

Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin

Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult senior

No variant requirements are available.